Whole-Genome Sequencing in Cancer Diagnostics: Feasibility, Actionability & Survival Outcomes

The landscape of cancer diagnostics is evolving, with increasing attention focused on the potential of comprehensive genomic sequencing. A recent study, published in Nature, investigated the real-world clinical utility of tumor whole-genome sequencing (WGS) in solid cancers, analyzing data from over 900 patients between January 2021 and November 2022. The findings suggest that WGS can provide valuable insights, particularly in complex cases like cancers of unknown primary origin, but also highlight the importance of careful sample preparation and data interpretation.

Feasibility and Turnaround Time in Routine Practice

The study assessed the feasibility of implementing WGS within a routine clinical setting. Researchers found that suitable tissue samples could be prepared for WGS in the vast majority of cases – 888 out of 935 patients initially requested for sequencing. Successful diagnostic reports were generated for 793 of those 888 samples, representing an 89% success rate. This suggests WGS is technically achievable in a significant proportion of patients. Yet, the quality of the initial tissue sample is crucial; 40% of failed cases stemmed from insufficient tumor cell percentage, even after efforts to enhance cellularity. The researchers addressed this by utilizing optimized DNA extraction methods for smaller samples, as detailed in a 2024 Nature Protocols publication ³⁴.

Importantly, the turnaround time for WGS results was relatively swift, with a median of 6 working days from sample reception to reporting. This is a critical factor for clinical utility, as timely results can directly impact treatment decisions. The range extended up to 22 days, indicating some variability depending on sample complexity and laboratory workflow.

Actionable Biomarkers and Treatment Implications

The core value of WGS lies in its ability to identify potentially actionable biomarkers – genetic alterations that can inform treatment strategies. The study found that 73% of patients (527 out of 723 with available data) harbored at least one such biomarker. These biomarkers indicated potential benefit from either reimbursed treatments or experimental therapies discussed within a molecular tumor board (MTB). The researchers also simulated the performance of smaller, more targeted next-generation sequencing (NGS) panels, finding that WGS detected a broader range of actionable biomarkers than either a 50-gene or 523-gene panel. In approximately 8% of patients, WGS revealed additional actionable biomarkers that would have been missed by comprehensive panel testing.

For patients with cancers of unknown primary (CUP), WGS proved particularly valuable. The study’s CUPPA algorithm (Cancer of Unknown Primary Prediction Algorithm) successfully predicted the tissue of origin in 49% of cases with high confidence, and in an additional 14%, aided in diagnosis when combined with other clinical findings. This is significant because identifying the primary tumor type is essential for guiding appropriate systemic therapy. A previous study by Schipper et al. ²⁷ also demonstrated the utility of WGS in resolving CUP diagnoses.

Beyond Treatment: Identifying Pathogenic Germline Variants

WGS also offers the opportunity to identify pathogenic germline variants (PGVs) – inherited genetic mutations that can increase cancer risk or influence treatment response. The study identified PGVs in 6.5% of patients, with about half of these not previously detected through routine diagnostics. These findings can have implications for family members and may warrant genetic counseling and further testing. It’s important to note that reporting of PGVs is evolving, with updated national guidelines now recommending reporting variants without explicitly stating germline status ⁴³.

Impact on Overall Survival

Perhaps the most compelling finding of the study was the association between biomarker-informed therapy and improved overall survival (OS). Patients with actionable biomarkers who received targeted treatment after WGS had a significantly longer median OS compared to those with actionable alterations who did not receive such treatment. The median OS increased from 309 to 405 days, representing a 31% improvement. This benefit was most pronounced in patients who had not previously received systemic therapy, suggesting that WGS is particularly valuable in guiding initial treatment decisions.

Understanding Hazard Ratios and Confidence Intervals

The study reports a hazard ratio (HR) of 0.78 with a 95% confidence interval (CI) of 0.63–0.96. This means that patients receiving biomarker-informed therapy had a 22% lower risk of death compared to those who did not (1 – 0.78 = 0.22). The 95% CI indicates the range within which the true HR likely lies; because the CI does not include 1, the result is statistically significant. It’s crucial to remember that this is an observational study, and therefore cannot definitively prove causation.

The Evolving Role of WGS in Cancer Care

The study demonstrates that WGS is a feasible and potentially impactful tool in routine cancer diagnostics. While challenges remain – including sample quality and data interpretation – the benefits of identifying actionable biomarkers and improving diagnostic accuracy are substantial. The researchers emphasize that WGS is not a one-size-fits-all solution, but rather a valuable addition to the oncologist’s toolkit, particularly for patients with complex or poorly understood cancers.

Looking ahead, continued research is needed to refine WGS workflows, validate biomarker findings, and develop clinical trials to evaluate the effectiveness of biomarker-guided therapies. The integration of WGS into routine clinical practice will likely require ongoing education for healthcare professionals and robust infrastructure to support genomic data analysis and interpretation. Further investigation into the optimal apply of WGS, particularly in specific cancer subtypes and clinical scenarios, will be crucial to maximizing its potential to improve patient outcomes.